Greenleaf Trust Sells 154 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Greenleaf Trust cut its position in Laboratory Co. of America Holdings (NYSE:LH) by 2.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,442 shares of the medical research company’s stock after selling 154 shares during the quarter. Greenleaf Trust’s holdings in Laboratory Co. of America were worth $1,248,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. SouthState Corp acquired a new stake in shares of Laboratory Co. of America in the 3rd quarter worth $28,000. Horizon Bancorp Inc. IN acquired a new stake in Laboratory Co. of America in the third quarter worth about $29,000. Fortitude Family Office LLC grew its stake in shares of Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after acquiring an additional 100 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 127 shares during the last quarter. Finally, Riverview Trust Co boosted its stake in Laboratory Co. of America by 172.6% in the 3rd quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock worth $38,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Activity at Laboratory Co. of America

In other news, EVP Der Vaart Sandra D. Van sold 1,000 shares of Laboratory Co. of America stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $239.42, for a total value of $239,420.00. Following the completion of the sale, the executive vice president now owns 2,670 shares of the company’s stock, valued at $639,251.40. The trade was a 27.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the transaction, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at $21,289,260.27. This trade represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,572 shares of company stock valued at $5,915,209 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Laboratory Co. of America Price Performance

Shares of LH opened at $247.49 on Tuesday. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59. The firm has a market capitalization of $20.70 billion, a PE ratio of 47.87, a P/E/G ratio of 1.86 and a beta of 1.07. The stock’s 50 day moving average is $236.02 and its two-hundred day moving average is $228.72.

Laboratory Co. of America Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is 55.71%.

Analyst Upgrades and Downgrades

LH has been the subject of several research reports. Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Barclays increased their price objective on Laboratory Co. of America from $249.00 to $271.00 and gave the company an “equal weight” rating in a report on Monday. Robert W. Baird increased their price target on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. HSBC upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $275.00 price objective (up from $265.00) on shares of Laboratory Co. of America in a report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $263.46.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.